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Available online 27 September 2018Background: Electrocardiographic (ECG) left ventricular hypertrophy (LVH) is an established risk factor for
cardiovascular events. However, limited data is available on the prognostic values of different ECG LVH criteria
speciﬁcally to sudden cardiac death (SCD). Our goal was to assess relationships of different ECG LVH criteria to
SCD.
Methods: Three traditional and clinically useful (Sokolow–Lyon, Cornell, RaVL) and a recently proposed (Peguero–
Lo Presti) ECG LVH voltage criteria were measured in 5730 subjects in the Health 2000 Survey, a national general
population cohort study. Relationships between LVH criteria, as well as their selected composites, to SCDwere an-
alyzed with Cox regression models. In addition, population-attributable fractions for LVH criteria were calculated.
Results: After amean follow-up of 12.5± 2.2 years, 134 SCDs had occurred.When used as continuous variables, all
LVH criteria except for RaVL were associated with SCD in multivariable analyses. When single LVH criteria were
used as dichotomous variables, only Cornell was signiﬁcant after adjustments. The dichotomous composite of
Sokolow–Lyon and Cornell was also signiﬁcant after adjustments (hazard ratio for SCD 1.82, 95% conﬁdence inter-
val 1.20–2.70, P = 0.006) and was the only LVH measure that showed statistically signiﬁcant population-
attributable fraction (11.0%, 95% conﬁdence interval 1.9–19.2%, P= 0.019).
Conclusions: Sokolow–Lyon, Cornell, and Peguero–Lo Presti ECG, but not RaVL voltage, are associatedwith SCD risk
as continuous ECG voltage LVH variables. When SCD risk assessment/adjustment is performed using a dichoto-
mous ECG LVH measure, composite of Sokolow–Lyon and Cornell voltages is the preferred option.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Electrocardiographic (ECG) left ventricular hypertrophy (LVH) is an
established risk factor for cardiovascular events [1–6]. ECG LVH is also
associated speciﬁcally with increased risk for sudden cardiac death
(SCD) [7,8], which is among the leading causes of death worldwide
[9]. Association between ECG LVH and SCD remains signiﬁcant alsoeart and Lung Center, Helsinki
, Finland.
).
eliability and freedom from bias
. This is an open access article underafter adjusting for anatomic measures of LVH (echocardiography
[echo], magnetic resonance imaging) [8,10,11], indicating that adverse
electrical remodelling per se conveys additional prognostic value.
ECG is widely used and a routine test, among others, in all individ-
uals with hypertension. Because of its potential implications, searching
for signs of LVH is one of the key steps in the ECG assessment. Several
ECG LVH criteria have been developed, but their prognostic values
have been compared in only a few studies [6,12–14] and there is even
more limited data comparing the prognostic values of different LVH
criteria speciﬁcally to SCD. The present study was performed to com-
pare the relationships of three traditional and clinically useful
(Sokolow–Lyon, Cornell, RaVL) and one recently proposed (Peguero–Lo
Presti) LVH voltage criteria, as well as their selected composites, to
SCD in the general population.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study population, electrocardiography
The Health 2000 Survey was a prospective, epidemiologic survey that was conducted
in Finland between 2000 and 2001. The survey population (n= 8028) was a two-stage
stratiﬁed cluster sample drawn from the population register and was representative of
the entire Finnish adult (≥30 years) general population. Survey procedures consisted of
a structured interview, a comprehensive health examination with questionnaires,
measurements, and a physician's clinical examination. Survey was highly successful
with almost 85% of the recruited subjects attending the health examination. Detailed
Health 2000 Survey methodology report is available online [15]. Survey was conducted
according to the recommendations of the Declaration of Helsinki, and was approved by
the Institutional Ethics Committee and by the Epidemiology Ethics Committee of the
Helsinki and Uusimaa Hospital District. Subjects gave written informed consent.
Digital 12‑lead ECGs were recorded at the Health 2000 Survey baseline with Mar-
quette MAC 5000 (GE Marquette Medical Systems, Milwaukee, WI). ECGs were available
from 6305 subjects. Subject with low ECG quality, complete left/right bundle branch
block, or incomplete covariate data were excluded. In addition, subjects aged N80 years
at the survey baseline were excluded from adjudication of the cause of death because of
the potential adjudication imprecision in this age group (due to high comorbidity rate
and low autopsy rate). After exclusions, a total of 5730 Health 2000 Survey subjects
were available for the present study. ECG measurements were performed on screen in a
blinded fashion by a single observer with methods described previously [16].
ECG LVH voltage amplitude criteria known as Sokolow–Lyon, Cornell, RaVL, and
Peguero–Lo Presti were selected for the present study. Sokolow–Lyon amplitude was cal-
culated as SV1 + RV5 or SV1 + RV6 (whichever was greater); dichotomous cutoff for LVH
was ≥3.5 mV [17]. Cornell amplitude was calculated as SV3 + RaVL; dichotomous cutoff
for LVH was N2.0 mV in women and N2.8 mV in men [18]. RaVL amplitude was measured
as RaVL; dichotomous cutoff for LVH was N1.1 mV [19]. Peguero–Lo Presti amplitude was
calculated as the deepest S among all 12 leads + SV4; dichotomous cutoff for LVH was
≥2.3 mV in women and ≥2.8 mV in men [20].
2.2. Follow-up and adjudication of the cause of death
Follow-up was from the Health 2000 Survey baseline until December 31, 2013.
Adjudication of the cause of death was performed blinded to ECG data as described
previously [21]. Brieﬂy, adjudication was based on national registers of drug reimburse-
ment, hospital admission and discharge diagnoses, and causes of deaths. Extensive
national registers are maintained in Finland, and data on all deaths of Finnish citizens
are collected systematically. Out-of-hospital deaths and deathswithin 10 days of hospital-
ization were considered eligible for the SCD adjudication. Data from registers were
analyzed independently by two physicians and classiﬁed deaths as probable, possible,
unlikely SCD, and unknown cause of death. Deaths inwhich a cardiac causewas the imme-
diate or underlying cause of death and the death was not known to be unrelated to
arrhythmiawere deﬁned as probable SCDs. Deaths in which the immediate or underlying
cause of deathwas noncardiac, but cardiac diseasewas present and could reasonably have
contributed to arrhythmia based on mechanism (e.g., unexpected death due to aspiration
in a patientwith a priormyocardial infarction), or deaths that could have been arrhythmic
based on circumstances (e.g., death of a driver in amotor vehicle crash, deathwhile swim-
ming) were deﬁned as possible SCDs. Deaths in which there was an explained medical
cause of death unrelated to cardiac disease (e.g., cancer, massive blood loss, sepsis, pulmo-
nary embolism, stroke) or a cardiac cause of death known to be nonsudden or unrelated to
lethal arrhythmia (e.g.,myocardial rupture aftermyocardial infarction, endocarditis)were
deﬁned as unlikely SCDs. Deaths with insufﬁcient data were deﬁned as deaths with
unknown cause. In case of disagreement on the cause of death, two additional indepen-
dent physicians reviewed the case, and ﬁnal decision was constituted by consensus.
Autopsies were performed in 67.2% of SCDs. In the present study, probable and possible
SCDs were pooled in the analyses and were classiﬁed as SCDs.
2.3. Statistical analysis
Analyses were performedwith R Statistics (version 3.4.0, The R Foundation for Statis-
tical Computing, Vienna, Austria; used for Cox regression analyses and spline ﬁgures),
STATA 13.0 (StataCorp, College Station, TX; used to calculate population-attributable frac-
tions), and SPSS (version 21, IBM, Armonk, NY; used for all other analyses). Values are
given asmean±SD for continuous variables, andpercentages andnumbers for categorical
variables. Bivariate correlations between continuous LVH variables were tested with
Pearson's test. Firth's penalized maximum likelihood bias reduction method for Cox re-
gression (R package: coxphf) was used to obtain the hazard ratios in the survival analyses
[22,23]. Concordance probability estimate was used to compare the predictive accuracy of
the continuous LVH variables for SCD (R package: CPE) [24]. The validity of proportional
hazards assumption was veriﬁed graphically with partial residual plots (continuous vari-
ables) and survival probability plots (dichotomous variables). LVH variables were used
both as continuous and dichotomous. Selected composite LVH criteria were also used.
Gender, study baseline age, bodymass index, heart rate, current smoking (yes/no), arterial
hypertension (yes/no), previous myocardial infarction (yes/no), and diabetes mellitus
(yes/no) were used as covariates in multivariable analyses. One LVH variable was used
in the multivariable models at a time. Deﬁnitions for arterial hypertension, previousmyo-
cardial infarction, and diabetes mellitus have been published [16]. Interaction term
(gender × LVH criterion) was tested in the same model together with main effects(i.e., LVH criterion, gender, all covariates). Cox models with penalized splines were used
to assess and plot the relationship of continuous LVH variables to SCD risk. Population-
attributable fractions were calculated for dichotomous ECG LVH criteria and selected
composite criteria from models including all covariates with a previously described
method [25] and implemented as the STATA module punafcc. Population-attributable
fraction reﬂects the proportion of events that can be attributed to a given risk marker or
the percentage of the cases thatwould be prevented if a speciﬁc exposurewere to be elim-
inated from the population. Two-tailed P b 0.05was considered signiﬁcant for all analyses.
3. Results
After a mean follow-up of 12.5 ± 2.2 years, 134 SCDs had occurred.
Baseline characteristics are shown in Table 1. Clinical variables showed
that, compared with subjects without SCD, subjects with SCD were
older, more often males, had higher body mass index and heart rate,
were more often smokers, hadmore often hypertension, previousmyo-
cardial infarction, and diabetes. ECG variables showed that, compared
with subjects without SCD, subjects with SCD had longer QRS and QTc
durations, higher voltages, and had more often LVH. Depending on the
criteria, LVH prevalence varied markedly. Peguero–Lo Presti showed
the highest prevalence, and was fulﬁlled in≈25% of all study subjects.
Hazard ratios of SCD for continuous LVH criteria are shown in
Table 2. In multivariable adjusted models, all criteria except for RaVL
remained signiﬁcantly associated with SCD. As an example, one milli-
meter increase in Cornell was associated with a 1.04-fold (95% conﬁ-
dence interval [CI] 1.01–1.07, P = 0.008) risk of SCD. Concordance
probability estimate was highest, 0.63 (95% CI 0.60–0.66), for Cornell,
while it was 0.56 (95% CI 0.52–0.60) for Sokolow–Lyon, 0.60 (95% CI
0.57–0.63) for Peguero–Lo Presti, and 0.59 (95% CI 0.56–0.62) for RaVL.
When continuous ECG LVH variables were used to test gender-LVH in-
teraction terms in multivariable Cox models, interactions were not
found (P N 0.114 for all gender-LVH interaction terms). Adjusted, con-
tinuous associations between SCD risk and the three voltage criteria
that were signiﬁcantly associated with SCD in adjusted models are
shown in Supplementary Fig. I (Panels A–C). Compared to Sokolow–
Lyon and Peguero–Lo Presti, increase in Cornell was associated with a
more pronounced SCD risk increase.
Hazard ratios of SCD for dichotomous LVH criteria are shown in
Table 3. Of the single criteria, only Cornell remained signiﬁcant after
adjustments. Of the composite criteria, only composite of Sokolow–
Lyon and Cornell remained signiﬁcant after adjustments. Overlap of di-
chotomous Sokolow–Lyon, Cornell, and Peguero–Lo Presti criteria is
shown in Fig. 1. Overlap between Sokolow–Lyon and Cornell was rela-
tively small. By contrast, Cornell became mostly embedded by Peguero–
Lo Presti. Bivariate correlation between continuous Cornell and
Peguero–Lo Presti criteria was high (r= 0.71, P b 0.001), whereas other
correlations were lower (Sokolow–Lyon vs. Cornell, r = 0.20, P b
0.001; Sokolow–Lyon vs. Peguero–Lo Presti, r = 0.21, P b 0.001).
When population-attributable fractions were calculated for dichoto-
mous ECG LVH criteria and selected composite criteria, population-
attributable fraction was 4.8% (95% CI –1.9–11.2%, P = 0.158) for
Sokolow–Lyon, 6.1% (95% CI –0.2–12.1%, P = 0.059) for Cornell,
9.5% (95% CI –2.3–20.0%, P = 0.111) for Peguero–Lo Presti, 2.0%
(95% CI –3.1–6.8%, P = 0.442) for RaVL, 11.0% (95% CI 1.9–19.2%, P =
0.019) for composite of Sokolow–Lyon and Cornell, 11.5% (95% CI –
2.1–23.3%, P = 0.095) for composite of Sokolow–Lyon and Peguero–
Lo Presti, and 8.3% (95% CI –3.7–18.9%, P=0.168) for composite of Cor-
nell and Peguero–Lo Presti. Thus, only composite of Sokolow–Lyon and
Cornell was statistically signiﬁcant.
4. Discussion
4.1. Main ﬁndings
Our study in white general population showed that Sokolow–Lyon,
Cornell, and Peguero–Lo Presti ECG voltage LVH criteria provided prognos-
tic information on SCD risk as continuous variables even after adjusting for
Table 1
Baseline characteristics of the study subjects.
No SCD
(n= 5596)
SCD
(n= 134)
P value
Clinical variables
Age, years 51 ± 13 62 ± 10 b0.001
Male gender, %(n) 46(2547) 78(104) b0.001
Body mass index, kg/m2 27 ± 5 28 ± 5 0.008
Heart rate, beats per minute 63 ± 11 68 ± 14 b0.001
Current smoking, %(n) 22(1248) 43(58) b0.001
Arterial hypertension, %(n) 45(2503) 75(100) b0.001
Previous myocardial infarction, %(n) 2(103) 19(25) b0.001
Diabetes mellitus, %(n) 5(290) 15(20) b0.001
ECG variables
QRS duration, ms 93 ± 9 98 ± 14 b0.001
QTc duration, msa 409 ± 25 423 ± 29 b0.001
Sokolow−Lyon voltage, mVb 2.5 ± 0.7 2.7 ± 0.9 0.022
Cornell voltage, mVc 1.5 ± 0.6 1.8 ± 0.7 b0.001
Peguero−Lo Presti voltage, mVd 2.1 ± 0.7 2.5 ± 1.0 b0.001
RaVL voltage, mVe 0.4 ± 0.3 0.6 ± 0.3 b0.001
ECG LVH by voltage criteria
Sokolow−Lyon, %(n)f 9(482) 14(19) 0.030
Cornell, %(n)g 7(386) 13(17) 0.016
Peguero−Lo Presti, %(n)h 25(1392) 34(45) 0.026
RaVL, %(n)i 4(215) 8(11) 0.021
Values are given asmean± SD for continuous variables, and percentages and numbers for
categorical variables.
LVH indicates left ventricular hypertrophy; SCD, sudden cardiac death.
a ThemaximumQT interval of all leads with Bazett's formula adjustment for heart rate.
b SV1 + RV5 or SV1 + RV6 (whichever was greater).
c SV3 + RaVL.
d SDeepest + SV4.
e RaVL.
f SV1 + RV5 or SV1 + RV6 (whichever was greater) ≥3.5 mV.
g SV3 + RaVL N 2.0 mV (women), N2.8 mV (men).
h SDeepest + SV4 ≥ 2.3 mV (women), ≥2.8 mV (men).
i RaVL N 1.1 mV.
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ments.When single LVH criteriawere used as dichotomous variables, only
Cornell was signiﬁcant after adjustments. The dichotomous composite of
Sokolow–Lyon and Cornell was also signiﬁcantly associated with SCD
after adjustments andwas the only LVHmeasure that showed statistically
signiﬁcant population-attributable fraction.
4.2. LVH as a modiﬁer of SCD risk
Myocardial ischemia is central in SCD, and coronary disease has been
estimated to account for≈80% all SCDs [26]. The secondmost common
etiology of SCD, with a proportion of 10–15%, is (hypertrophic andTable 2
Hazard ratios of SCD for continuous ECG LVH criteria from Cox models.
Modela LVH voltage criteria HR (95% CI)b P value
Unadjusted Sokolow–Lyonc 1.03 (1.01–1.06) 0.003
Cornelld 1.09 (1.06–1.12) b0.001
Peguero–Lo Prestie 1.05 (1.03–1.07) b0.001
RaVLf 1.12 (1.07–1.16) b0.001
Multivariable adjusted Sokolow–Lyon 1.02 (1.003–1.05) 0.030
Cornell 1.04 (1.01–1.07) 0.008
Peguero–Lo Presti 1.03 (1.01–1.05) 0.002
RaVL 1.03 (0.98–1.09) 0.262
CI indicates conﬁdence interval; otherwise, abbreviations as in Table 1.
a Covariates in the multivariate analyses: gender, age at the study baseline, body mass
index, heart rate, current smoking (yes/no), arterial hypertension (yes/no), diabetes
mellitus (yes/no), previous myocardial infarction (yes/no).
b Hazard ratio per 100 μV (1 mmwith the 10 mm/mV calibration) increase in the ECG
LVH measure value.
c SV1 + RV5 or SV1 + RV6 (whichever was greater).
d SV3 + RaVL.
e SDeepest + SV4.
f RaVL.dilated) cardiomyopathy [26]. Hypertrophied myocardium predisposes
to malignant arrhythmias by various mechanisms. These include,
among others, reduced coronary blood ﬂow predisposing to ischemia;
cardiomyocyte loss and increased ﬁbrosis creating a substrate for elec-
tric reentry and increased dispersion of repolarization [27]; arrhythmo-
genic alterations in cardiomyocyte ion channel expression and function
predisposing to afterdepolarizations [28]. In hypertrophic cardiomyop-
athy, SCD risk has been reported to increase with the maximum left
ventricular (LV) wall thickness [29]. Importantly, even in the absence
of coronary disease or cardiomyopathy, increase in echo LV mass al-
ready within normal to mildly elevated range is linearly associated
with adverse changes in ECG repolarization measures [30]. Thus, in
the presence of ischemia, SCD risk may be assumed to be modiﬁed, in
addition to other factors (e.g., electrolyte disturbances, genetic factors),
by the degree of pathological myocardial hypertrophy.
4.3. ECG LVH and anatomic LVH in relation to SCD risk
Increase in risk-factor adjusted hazard ratio for SCD has been re-
ported in the general population both for ECG LVH [7,8,31] and echo
LVH [32–35]. Of note, LVH diagnosed by ECG vs. echo or magnetic reso-
nance imaging contains distinct prognostic value for SCD risk [8,10,11],
showing that ECG LVH is a marker of adverse electric remodelling even
in the absence of anatomic hypertrophy. Simulation studies indicate
that electric properties of the heart, especially slowed electric conduc-
tion velocity (ﬁbrosis), may also increase ECG QRS voltages and may
thus explain whymany subjects with ECG LVH do not present with an-
atomic LVH (and vice versa), and why both ECG LVH and anatomic LVH
convey prognostic value independent of each other [36]. Highlighting
the importance of LVH, echo LVH has been reported as at least equiva-
lent to severely decreased LV ejection fraction as a predictor ofmortality
or SCD [37]. Recently, in an epidemiologic case-control study, the Ore-
gon Sudden Unexpected Death Study (Oregon SUDS), an ECG risk
score which included ECG LVH (composite of Sokolow–Lyon and Cor-
nell voltages) as a score component resulted in signiﬁcant additive im-
provement above LV ejection fraction in SCD risk estimation [38].
Despite the conﬁrmed link between LVH and SCD, little has been
known about the prognostic values of different ECG LVH criteria specif-
ically to SCD. The prognostic values of different LVH criteria for incident
cardiovascular events vary [14], suggesting that some criteria may out-
perform others in stratifying speciﬁcally SCD risk. Previous studies
showing the relationship between ECG LVH and SCD have mainly re-
ported one single LVHmeasure. In one of the earliest studies, Minnesota
code 3–1 was used [31], whereas in another report from the 1970's the
deﬁnition for ECG LVH was not speciﬁed [7]. In the Oregon SUDS,
Sokolow–Lyon voltage was used as a dichotomous ECG LVH variable
and was associated with sudden cardiac arrest also after adjusting for
other risk factors, including echo LVH [8]. More recently in the Oregon
SUDS, Romhilt–Estes score ≥5 (“deﬁnite LVH”)was associatedwith sud-
den cardiac arrest in the adjusted model [39].
Our present study may be the ﬁrst comprehensive comparison on
the performance of several LVH criteria as risk predictors of SCD.
Three traditional and clinically useful and one recently proposed LVH
criteria were analyzed both as continuous and dichotomous. Data
were collected prospectively. First, as expected, signiﬁcant associations
between traditional risk factors and SCD was observed. Second, LVH
prevalence varied markedly between criteria, which is not surprising
as similar has been reported previously [6,14]. Prevalence of Peguero–
Lo Presti showed a relatively high prevalence (≈25% of all subjects).
Our studymay be the ﬁrst reporting the prevalence of this new criterion
in the general population. In their work including mainly hypertensive
hospital patients, Peguero et al. reported that, compared to Sokolow–
Lyon, Cornell, and RaVL, Peguero–Lo Presti criterion hadmarkedly higher
sensitivity and lower speciﬁcity for detecting echo LVH [20]. Thus, our
results showing higher LVH prevalence rates for Peguero–Lo Presti
compared to other criteria are in line with the previous report [20].
Table 3
Hazard ratios of SCD for dichotomous ECG LVH criteria from Cox models.
Modela LVH voltage criteria HR (95% CI) P Value
Single criteria
Unadjusted Sokolow–Lyonb 1.79 (1.07–2.81) 0.027
Cornellc 2.06 (1.20–3.31) 0.010
Peguero–Lo Prestid 1.53 (1.06–2.17) 0.023
RaVLe 2.40 (1.24–4.20) 0.012
Multivariable adjusted Sokolow–Lyon 1.55 (0.92–2.48) 0.096
Cornell 1.97 (1.12–3.29) 0.021
Peguero–Lo Presti 1.40 (0.97–2.00) 0.072
RaVL 1.36 (0.69–2.43) 0.346
Composite criteria
Unadjusted Sokolow–Lyon and/or Cornell 1.98 (1.32–2.89) 0.001
Sokolow–Lyon and/or Peguero–Lo Presti 1.56 (1.10–2.19) 0.013
Cornell and/or Peguero–Lo Presti 1.44 (1.003–2.05) 0.048
Multivariable adjusted Sokolow–Lyon and/or Cornell 1.82 (1.20–2.70) 0.006
Sokolow–Lyon and/or Peguero–Lo Presti 1.40 (0.98–1.99) 0.061
Cornell and/or Peguero–Lo Presti 1.33 (0.92–1.91) 0.124
Abbreviations as in Tables 1 and 2.
a Covariates in the multivariate analyses as in Table 2.
b SV1 + RV5 or SV1 + RV6 (whichever was greater) ≥3.5 mV.
c SV3 + RaVL N 2.0 mV (women), N2.8 mV (men).
d SDeepest + SV4 ≥ 2.3 mV (women), ≥2.8 mV (men).
e RaVL N 1.1 mV.
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pertension and that echo is more sensitive than ECG in detecting ana-
tomic LVH, it seems plausible that the cutoff value for Peguero–Lo
Presti in the white adult general population should be higher than
that proposed by Peguero et al. [20] We do admit that future studies
are needed to answer this in more detail as data on echo LVH were
not available in our study.
Third, when LVH criteria were analyzed as continuous variables in
multivariable adjusted models, Sokolow–Lyon, Cornell, and Peguero–
Lo Presti remained associated with SCD. By contrast, RaVL lost its associ-
ationwith SCD. ECGQ, R, and Swaves are believed to represent different
parts of the depolarizing areas in the heart. Speciﬁcally, Q and R waves
represent depolarization of the interventricular septum, conduction
system, and LV endomyocardium, whereas S waves are believed to
represent the depolarization of the ventricular free wall and myocar-
dium [20]. It has been postulated that, compared to S waves, R waves
are less sensitive in detecting mild to moderate anatomic LVH [20]. In
contrast to this, RaVL has also been reported to perform as good orFig. 1. Overlap of dichotomous ECG LVH voltage criteria. Sokolow–Lyon: SV1 + RV5 or SV1
+ RV6 (whichever was greater) ≥3.5 mV; Cornell: SV3+ RaVL N 2.0 mV (women), N2.8 mV
(men); Peguero–Lo Presti: SDeepest + SV4 ≥ 2.3 mV (women), ≥2.8 mV (men).even better in echo LVH detection compared to Sokolow–Lyon and
Cornell [5]. Risk-factor adjusted association between RaVL and cardio-
vascular outcomes has been reported [5,14], but also conﬂicting results
have been published [6]. We report here as a new ﬁnding that RaVL as a
sole criterion does not seem to capture the malignant arrhythmogenic
risk of LVH in the general population.
Fourth, when LVH criteria were used in the present study as dichot-
omous variables, relationships of Sokolow–Lyon and Peguero–Lo Presti
to SCD were nonsigniﬁcant in multivariable adjusted models although
they were signiﬁcant when used as continuous variables. One explana-
tion for this may be diminished statistical power related to dichotomi-
zation. The composite of Sokolow–Lyon and Cornell was the only
composite criterion that remained signiﬁcantly associated with SCD
after adjustments. In addition, composite of Sokolow–Lyon and Cornell
was the only criterion that showed statistically signiﬁcant population-
attributable fraction. Use of composite LVH criteria is generally
supported because of expected enhanced sensitivity in LVH detection.
When criteria are selected, a logical step is to combine criteria that are
both associatedwith outcome and also capture different patient catego-
ries, such as Sokolow–Lyon and Cornell.We have previously reported in
the Health 2000 Survey that composite of Sokolow–Lyon and Cornell
voltages performed the best in predicting incident cardiovascular
events [14]. Results of the present study conﬁrm that composite of
Sokolow–Lyon and Cornell is also valid when SCD is the endpoint.
4.4. Limitations
Our study was performed in white general population. Future
studies may evaluate whether our ﬁndings are reproducible also in
multiracial populations as well as in populations with a more elevated
SCD risk, such as in coronary heart disease and/or previous myocardial
infarction.
4.5. Conclusions
Sokolow–Lyon, Cornell, and Peguero–Lo Presti ECG, but not RaVL
voltage, are associated with SCD risk as continuous ECG voltage LVH
variables. When SCD risk assessment/adjustment is performed using a
dichotomous ECG LVH measure, composite of Sokolow–Lyon and
Cornell voltages is the preferred option.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2018.09.104.
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